(Total Views: 131)
Posted On: 11/29/2018 5:37:43 PM
Post# of 154148
NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PCaTest Clinical Study Results Demonstrate Added Value to Gleason Score, Further Support FDA filing
Biotechnology company CytoDyn (OTCQB: CYDY) today announced recent clinical study results showing that its PCaTest provides substantial additive value for predicting outcomes for prostate cancer patients compared to the Gleason score, the current standard for prostate cancer diagnosis. The new findings support CYDY’s strategy for seeking FDA approval for the PCaTest. “Unfortunately, current tests not able to precisely determine whether an individual’s cancer will result in death if not treated aggressively,” CytoDyn Chief Medical Officer and developer of the PCaTest Richard Pestell , M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “On the other hand, aggressive treatment for prostate cancer has significant long-term side effects that can include incontinence, erectile dysfunction and dribbling, and should be avoided if possible. The PCaTest uses a proprietary artificial intelligence approach designed to yield a more accurate prognostic result. In essence, we believe the test is designed to identify with greater certainty patients whose lives are at risk if they don’t have their prostate removed. The test is being developed to show gene signatures can help guide patients and their doctors to make better informed decisions about treatment.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) today announced recent clinical study results showing that its PCaTest provides substantial additive value for predicting outcomes for prostate cancer patients compared to the Gleason score, the current standard for prostate cancer diagnosis. The new findings support CYDY’s strategy for seeking FDA approval for the PCaTest. “Unfortunately, current tests not able to precisely determine whether an individual’s cancer will result in death if not treated aggressively,” CytoDyn Chief Medical Officer and developer of the PCaTest Richard Pestell , M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “On the other hand, aggressive treatment for prostate cancer has significant long-term side effects that can include incontinence, erectile dysfunction and dribbling, and should be avoided if possible. The PCaTest uses a proprietary artificial intelligence approach designed to yield a more accurate prognostic result. In essence, we believe the test is designed to identify with greater certainty patients whose lives are at risk if they don’t have their prostate removed. The test is being developed to show gene signatures can help guide patients and their doctors to make better informed decisions about treatment.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
